NSE / BSEHealthcare
βΉ22522.85-1013.35-4.31%
P/E94.3Mkt CapβΉ18.38 K CrEV/EBITDA38.6
Neuland Laboratories Limited.
P/E94.3Mkt CapβΉ18.38 K CrEV/EBITDA38.6
Company Profile
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Valuation
Market Cap
βΉ0.00
β
Current Price
βΉ0
βas of 15 Sept 2026
P/E Ratio
0.0x
β
P/B Ratio
0.0x
β
EV / EBITDA
0.0x
β
EV / Sales
0.0x
β
52W High
βΉ0
β
52W Low
βΉ0
β
Shares Out
0.00 Cr
β
Profitability
Operating Margin
0.0%
β
Net Profit Margin
0.0%
β
EBITDA Margin
0.0%
β
Returns
ROE
0.0%
β
ROCE
0.0%
β
ROIC %
β
β
ROA
0.0%
β
Dividend Payout
0.0%
β
Solvency
Current Ratio
0.0x
β
Debt / Equity
0.0x
β
Debt / Assets
0.0x
β
CFO / Net Profit
0.0x
β
Interest Coverage
0.0x
β
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 15.4%
Concerns0
Rule-based from financial data. Not advice.
Price Historyβ² 43.53% over 1Y
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
RevenueβΉ1.48 K CrβΌ 5.3%
EBITDA Growthβ
Net ProfitβΉ259.00 CrβΌ 13.7%
Cash from Ops (CFO)β
Free Cash Flow (FCF)ββ² 7.3%
Revenue CAGR 5Y15.4%
EBITDA CAGR 5Y35.2%
Net Profit CAGR 5Y79.7%
NP Growth 1Y-13.7%
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.48 K Cr | β | βΉ259.00 Cr | β | β | 17.1% | -5.3% | -13.7% |
| Mar 2024 | βΉ1.56 K Cr | β | βΉ300.00 Cr | β | β | 23.5% | 30.9% | 84.0% |
| Mar 2023 | βΉ1.19 K Cr | β | βΉ163.00 Cr | β | β | 16.5% | 25.2% | 154.7% |
| Mar 2022 | βΉ951.00 Cr | β | βΉ64.00 Cr | β | β | 7.7% | 1.5% | -20.0% |
| Mar 2021 | βΉ937.00 Cr | β | βΉ80.00 Cr | β | β | 10.2% | 22.8% | 400.0% |
| Mar 2020 | βΉ763.00 Cr | β | βΉ16.00 Cr | β | β | 2.3% | 14.4% | 0.0% |
| Mar 2019 | βΉ667.00 Cr | β | βΉ16.00 Cr | β | β | 2.3% | 26.6% | 33.3% |
| Mar 2018 | βΉ527.00 Cr | β | βΉ12.00 Cr | β | β | 2.2% | -9.0% | -73.9% |
| Mar 2017 | βΉ579.00 Cr | β | βΉ46.00 Cr | β | β | 8.5% | 13.5% | 76.9% |
| Mar 2016 | βΉ510.00 Cr | β | βΉ26.00 Cr | β | β | 14.1% | 8.7% | 62.5% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Free plan Β· showing 1 year of data.Upgrade
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,533 |
| Total Expenses | 1,207 |
| EBIT / Operating Profit | 327 |
| OPM % | 21% |
| Other Income | 77 |
| Finance Costs | 14 |
| Depreciation & Amortisation | 76 |
| Profit Before Tax | 313 |
| Tax % | - |
| Net Profit / PAT | 239 |
| EPS (βΉ) | 186.51 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Neuland Laboratories Limited.this co. | βΉ18.38 K Cr | βΉ1.48 K Cr | 94.30 | 11.40 | 38.56 | -5.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |